CerRx Receives $1.1 Million NIH Grant for Cancer Study - MyHighPlains.com
CerRx, Inc. (CerRx) today [Thursday] announced that it has been awarded a non-diluting National Institute of Health (NIH) grant of $1.1M to support a Phase I study combining its two lead investigational compounds intravenous (IV) fenretinide and IV safingol. These drugs act together to specifically kill cancer cells by increasing certain toxic ‘ceramide’ waxes in cancer cells.
C. Patrick Reynolds, M.D., Ph.D., chief scientific officer of CerRx and director at the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine Cancer Center, said, “The combination of fenretinide plus safingol provides a very exciting and novel approach to selectively attacking cancer cells of many types in adults and children and we are delighted that this imporant clinical trial will be carried out here in Texas.”
Read the full story >>
The Texas Tech University Health Sciences Center (TTUHSC) Graduate School of Biomedical Sciences hosted its 34th Annual Student Research Week March 8-11.
The National Cancer Institute awarded a five-year, $1.9 million grant to C. Patrick Reynolds, M.D., Ph.D., director for the School of Medicine Cancer Center at TTUHSC.
Equip Yourself with Lifesaving Skills – Know How to Stop the Bleed During National Stop the Bleed Month
Brittany Bankhead, M.D., an assistant professor of surgery for the Division of Trauma, Burns and Critical Care at the Texas Tech University Health Sciences Center, said life-threatening bleeding can happen in everyday scenarios.
TTUHSC celebrated the completion of the School of Health Professions Physician Assistant Program expansion May 16 with a ceremonial ribbon cutting.